3rd Edition 2022
Book
Softcover, 17,1 x 24,1 cm, 104 pages, 105 illus
Language: English
Categories: Interdisciplinary, Oral Surgery
ISBN 978-1-64724-089-9
QP USA
Buy this product from the following publishers:
Buy at QP Deutschland Buy at QP United Kingdom Buy at QP USA
This title is also available as eBook. Please check your favorite online eBook outlet on your device (Apple iBooks, Amazon Kindle, Tolino, and many more).
Drug-induced osteonecrosis of the jaws (DIONJ) is something oral surgeons are all too familiar with. For decades, Dr Marx has advocated drug holidays and other clinical tactics that can help mitigate the effects of bisphosphonates and other DIONJ-causing agents, particularly in patients being treated for osteoporosis or cancer. This book provides doctors and surgeons with the strategies and guidelines to treat DIONJ effectively and prevent it whenever possible. The first chapter explains the mechanism of action of DIONJ as well as its risk factors and staging, and the following chapters outline how to diagnose, treat, and even prevent DIONJ in patients with osteoporosis and cancer. Twenty cases are included to show how DIONJ presents clinically and what to do in each situation based on severity and patient condition. As the avoidance of DIONJ-causing drugs is not always feasible in the treatment of cancer, Dr Marx gives clear and practical information on how best to handle each situation, so oral surgeons and other clinicians can decide on the best possible treatment plans for their patients.
Contents
Chapter 1. Understanding Drug-Induced Osteonecrosis of the Jaws
Chapter 2. Prevention and Management of DIONJ in Patients Treated for Osteopenia/Osteoporosis
Chapter 3. Prevention and Management of DIONJ in Cancer Patients Taking Drugs Known to Cause DIONJ
Well known as an educator, researcher, and innovative surgeon, Dr Marx is professor of surgery and chief of the Division of Oral and Maxillofacial Surgery at the University of Miami Miller School of Medicine. As a researcher, he has made valuable contributions in the use of hyperbaric oxygen following radiation therapy, in the development of platelet-rich plasma, and in elucidating the relationships between smoking and carcinogenesis. He also pioneered the clinical applications of recombinant human bone morphogenetic protein and stem cell use and was the first to identify what is now known worldwide as bisphosphonate-induced osteonecrosis of the jaws. He has also developed new concepts and treatments for pathologies within OMS as well as new techniques in reconstructive surgery.
